Verdiperstat Emerging Drug Insight and Market Forecast – 2032

Verdiperstat Emerging Drug Insight and Market Forecast – 2032

“Verdiperstat Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about Verdiperstat for Amyotrophic Lateral Sclerosis in the 7MM. A detailed picture of the Verdiperstat for Amyotrophic Lateral Sclerosis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the Verdiperstat for Amyotrophic Lateral Sclerosis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Verdiperstat market forecast, analysis for Amyotrophic Lateral Sclerosis in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Amyotrophic Lateral Sclerosis.

Drug Summary

Verdiperstat (formerly named AZD3241) is a first-in-class, potent, selective, brain-permeable, irreversible myeloperoxidase (MPO) enzyme inhibitor. MPO is believed to play an essential role in multiple neurodegenerative diseases because it increases oxidative stress and inflammation levels in the nervous system. Inhibiting MPO is anticipated to ameliorate these pathological mechanisms, which are strongly implicated in ALS’s onset and progression.

Verdiperstat was licensed from AstraZeneca in 2018. AstraZeneca completed seven clinical studies that provided evidence that Verdiperstat achieves peripheral target engagement (i.e., reduces MPO specific activity in plasma) and central target engagement in the brain and offers proof of its mechanism of action (i.e., reduce microglial activation and neuroinflammation). It was selected as an investigational therapy for inclusion in the first HEALEY ALS platform trial by an independent scientific advisory committee in September 2019 and is currently in Phase II/III clinical trial for the treatment of ALS. The company has completed enrollment in Phase II/III, and top-line results are anticipated in mid-2022.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the Verdiperstat description, mechanism of action, dosage and administration, research and development activities in Amyotrophic Lateral Sclerosis.

Elaborated details on Verdiperstat regulatory milestones and other development activities have been provided in this report.

The report also highlights the Verdiperstat research and development activity in Amyotrophic Lateral Sclerosis details across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around Verdiperstat.

The report contains forecasted sales of Verdiperstat for Amyotrophic Lateral Sclerosis till 2032.

Comprehensive coverage of the late-stage emerging therapies for Amyotrophic Lateral Sclerosis.

The report also features the SWOT analysis with analyst views for Verdiperstat in Amyotrophic Lateral Sclerosis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Verdiperstat Analytical Perspective by DelveInsight

In-depth Verdiperstat Market Assessment

This report provides a detailed market assessment of Verdiperstat in Amyotrophic Lateral Sclerosis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

Verdiperstat Clinical Assessment

The report provides the clinical trials information of Verdiperstat for Amyotrophic Lateral Sclerosis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Amyotrophic Lateral Sclerosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Verdiperstat dominance.

Other emerging products for Amyotrophic Lateral Sclerosis are expected to give tough market competition to Verdiperstat and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Verdiperstat in Amyotrophic Lateral Sclerosis.

Our in-depth analysis of the forecasted sales data of Verdiperstat from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Verdiperstat in Amyotrophic Lateral Sclerosis.

Key Questions

What is the product type, route of administration and mechanism of action of Verdiperstat?

What is the clinical trial status of the study related to Verdiperstat in Amyotrophic Lateral Sclerosis and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Verdiperstat development?

What are the key designations that have been granted to Verdiperstat for Amyotrophic Lateral Sclerosis?

What is the forecasted market scenario of Verdiperstat for Amyotrophic Lateral Sclerosis?

What are the forecasted sales of Verdiperstat in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available in Amyotrophic Lateral Sclerosis and how are they giving competition to Verdiperstat for Amyotrophic Lateral Sclerosis?

Which are the late-stage emerging therapies under development for the treatment of Amyotrophic Lateral Sclerosis?